CN110799210A - 选择性消耗抗原特异性抗体的融合蛋白 - Google Patents

选择性消耗抗原特异性抗体的融合蛋白 Download PDF

Info

Publication number
CN110799210A
CN110799210A CN201780084570.5A CN201780084570A CN110799210A CN 110799210 A CN110799210 A CN 110799210A CN 201780084570 A CN201780084570 A CN 201780084570A CN 110799210 A CN110799210 A CN 110799210A
Authority
CN
China
Prior art keywords
seldeg
seq
antigen
protein
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780084570.5A
Other languages
English (en)
Chinese (zh)
Inventor
E·S·W·奥伯
V·S·C·德范纳波伊纳
R·J·奥伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Publication of CN110799210A publication Critical patent/CN110799210A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201780084570.5A 2016-12-02 2017-12-01 选择性消耗抗原特异性抗体的融合蛋白 Pending CN110799210A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662429367P 2016-12-02 2016-12-02
US62/429,367 2016-12-02
PCT/US2017/064186 WO2018102668A1 (en) 2016-12-02 2017-12-01 Fusion proteins for selectively depleting antigen-specific antibodies

Publications (1)

Publication Number Publication Date
CN110799210A true CN110799210A (zh) 2020-02-14

Family

ID=62242041

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780084570.5A Pending CN110799210A (zh) 2016-12-02 2017-12-01 选择性消耗抗原特异性抗体的融合蛋白

Country Status (7)

Country Link
US (2) US11459396B2 (enExample)
EP (1) EP3548073A4 (enExample)
JP (4) JP7295799B2 (enExample)
CN (1) CN110799210A (enExample)
AU (2) AU2017366674B2 (enExample)
CA (1) CA3045797A1 (enExample)
WO (1) WO2018102668A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120624489A (zh) * 2025-08-18 2025-09-12 天津医科大学总医院 一种嵌合aqp4抗体受体、caar-t细胞及应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020518240A (ja) * 2017-01-17 2020-06-25 ザ テキサス エー アンド エム ユニバーシティー システム 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
TWI922495B (zh) 2020-09-23 2026-04-21 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
WO2022063879A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
KR20230074775A (ko) 2020-09-23 2023-05-31 아블레비아 바이오테크 게엠베하 바이러스 벡터의 효능 증가를 위한 화합물
WO2022063887A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for increasing the efficacy of factor viii replacement therapy
EP4217402A1 (en) 2020-09-23 2023-08-02 Ablevia biotech GmbH Compound for the prevention or treatment of autoantibody-mediated conditions
CN116710143A (zh) 2020-09-24 2023-09-05 艾柏力维亚生技有限公司 用于预防或治疗重症肌无力的化合物
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses
CN119013290A (zh) 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子
AU2023367846A1 (en) * 2022-10-26 2025-05-01 Amgen Inc. Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016414A2 (en) * 2000-08-22 2002-02-28 Micromet Ag Composition for the elimination of autoreactive b-cells
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
JP2012503007A (ja) * 2008-09-17 2012-02-02 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002236499A1 (en) 2000-11-30 2002-06-11 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012150319A1 (en) * 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
CN106103476B (zh) * 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
US20160060358A1 (en) 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance
US20170334962A1 (en) * 2016-05-19 2017-11-23 Texas A&M University System FcRn-TARGETED ANTIGEN FUSION PROTEINS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016414A2 (en) * 2000-08-22 2002-02-28 Micromet Ag Composition for the elimination of autoreactive b-cells
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
JP2012503007A (ja) * 2008-09-17 2012-02-02 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HA JH等: "Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120624489A (zh) * 2025-08-18 2025-09-12 天津医科大学总医院 一种嵌合aqp4抗体受体、caar-t细胞及应用

Also Published As

Publication number Publication date
AU2025202131A1 (en) 2025-04-10
AU2017366674B2 (en) 2025-01-02
JP2020500885A (ja) 2020-01-16
JP2026097946A (ja) 2026-06-16
EP3548073A4 (en) 2020-07-22
US20200031948A1 (en) 2020-01-30
JP2023113894A (ja) 2023-08-16
JP7832913B2 (ja) 2026-03-18
CA3045797A1 (en) 2018-06-07
JP2025131743A (ja) 2025-09-09
US20230087965A1 (en) 2023-03-23
JP7295799B2 (ja) 2023-06-21
US11459396B2 (en) 2022-10-04
AU2017366674A1 (en) 2019-06-20
EP3548073A1 (en) 2019-10-09
WO2018102668A1 (en) 2018-06-07
US12404339B2 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
US12404339B2 (en) Method of depleting target antigen-specific antibody from a patient by administering a fusion protein (Seldeg) for selectively depleting antigen-specific antibodies
JP2022185021A (ja) 多価多重特異性ｏｘ４０結合融合タンパク質
CN109715663B (zh) 结合生长抑素受体2的异源二聚抗体
KR102562519B1 (ko) IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
EP3242891B1 (en) Monomeric fc domains
US20160009824A1 (en) Tetravalent bispecific antibodies
JP7793774B2 (ja) メソテリン結合タンパク質及びその使用
JP2020500885A5 (enExample)
EP4303231A1 (en) Bispecific antibody
TW202525853A (zh) 抗ｃｄ２０ｘ抗ｃｄ２８組合療法
KR20240052030A (ko) 높은 열 안정성 및 감쇠된 효과기 기능을 갖는 fc 변이체
CN118541393A (zh) 间皮素结合蛋白及其用途
US20260035435A1 (en) Approaches for the selective depletion of pla2r-specific antibodies
CN115066275A (zh) 包含修饰的ehd2结构域的结合模块
WO2026064598A1 (en) Approaches for the selective depletion of adamts13-specific antibodies
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途
JP2025531618A (ja) 内在性アゴニズムの高い抗ｃｄ４０抗体構築体
CN118119402A (zh) 工程化抗her2双特异性蛋白
EA051713B1 (ru) Биспецифическое антитело
HK40007765A (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200214

WD01 Invention patent application deemed withdrawn after publication